$1.17+0.03 (+2.63%)
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia.
Bionano Genomics, Inc. in the Healthcare sector is trading at $1.17 with a market capitalization of $13M. Wall Street consensus targets $5.00 (2 analysts), implying a +327.4% move over the next 12 months. The stock is currently near its 52-week low of $1.06, remaining 19.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.69Mβ | $7.95Mβ | $7.37Mβ | $6.73Mβ | $6.46M |
| Gross Profit | $3.25Mβ | $3.40Mβ | $3.37Mβ | $3.48Mβ | $2.94M |
| Operating Income | -$7.90Mβ | -$8.54M | -$8.54Mβ | -$7.80Mβ | -$8.46M |
| Net Income | -$8.30Mβ | -$7.93Mβ | -$8.50Mβ | -$6.86Mβ | -$3.10M |
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that ...
Bionano Genomics (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
By Karen Roman Prenetics Global Limited (Nasdaq: PRE) confirmed its multi-year partnership with #1 New York Times bestselling author and award-winning podcast host of On Purpose, Jay Shetty, making him [β¦]
Moby summary of Bionano Genomics, Inc.'s Q1 2026 earnings call
Bionano Genomics Inc (BNGO) reports strong revenue growth and operational efficiencies, but faces supply constraints and leadership transitions.